Reading orientation
Use the same steps for each treatment guide
This guide does not add clinical claims or rank treatments. Read the sourced answers and their limits. Take personal treatment decisions to a qualified clinician.
Before you compare
- Name your question or decision
- Find the sourced answer for it
- Check what the sources support
- Read what is still unknown
- Save questions to take to a clinician
Read each guide for its details
Each guide has its own sourced wording and limitations. This table cannot replace those details.
Open the full comparison guide →| Guide category | How to use this link | Guide |
|---|---|---|
| No active treatment and appearance choices | Read the guide and its sources. Note its limits and save questions. | Explore |
| Prescription topicals | Read the guide and its sources. Note its limits and save questions. | Explore |
| Phototherapy | Read the guide and its sources. Note its limits and save questions. | Explore |
| Pills, injections, and research treatments | Read the guide and its sources. Note its limits and save questions. | Explore |
| Procedures | Read the guide and its sources. Note its limits and save questions. | Explore |
| Complementary approaches | Read the guide and its sources. Note its limits and save questions. | Explore |
For people with vitiligo and their caregivers
What this page helps you do
Orient yourself to realistic paths, compare them consistently, and prepare for a shared decision without treating this page as a recommendation.
- Your task
- Choose the goal and trade-offs you want to discuss, then bring the comparison to a qualified clinician.
- The clinician boundary
- Confirming the diagnosis and activity, judging body-site and health factors, and selecting or monitoring a treatment plan belong to a qualified clinician.
Compare the paths before choosing one
These are categories, not a ranked treatment ladder. Compare only the paths that are realistic for you with a clinician.
Wait or choose no active treatment
When treatment is not wanted now, or its burden outweighs the goal.
Avoids treatment burden while leaving room to revisit the decision.
Does not aim to restore pigment or stop change.
Low treatment burden; still agree on skin protection, support, and review.
Usually does not depend on treatment coverage.
The choice is reversible, but vitiligo may change while you wait.
Camouflage and supportive care
When the immediate goal is appearance, confidence, or day-to-day support.
Can change appearance immediately and support wellbeing.
Does not treat pigment loss; products can irritate or transfer.
Application, removal, product matching, and cost vary.
Cosmetic and support resources vary and may be self-paid.
Usually reversible; product fit is individual.
Prescription creams or ointments
When a clinician thinks a topical option matches the diagnosis, body area, and goal.
Some options improve repigmentation for some people studied.
Products have different labels, evidence, precautions, and risks.
Regular application and follow-up can be substantial.
Prescription coverage and authorization vary.
Treatment can be stopped with clinical guidance; personal response is uncertain.
Clinician-directed light treatment
When phototherapy is clinically appropriate and repeated visits or home treatment are workable.
Can support repigmentation for some patterns and body areas.
Response varies and qualified oversight and precautions remain necessary.
Repeated sessions, travel or home-device routines, and follow-up.
Clinic capacity, device coverage, and supplier rules can limit access.
Sessions can be paused by the care team; result and durability vary.
Whole-body or research medicines
Only in selected clinical situations or a properly governed study.
May target broader disease activity or answer an unmet need.
Status, evidence, monitoring, and material risks differ by exact medicine.
Clinical monitoring and uncertainty may be higher.
Approval, specialist care, trials, and coverage differ.
Stopping does not erase every risk; early evidence may change.
Specialist procedures
For carefully selected stable vitiligo in experienced settings.
May restore pigment in selected patches.
Healing, incomplete or uneven results, and procedure risks matter.
Assessment, procedure, recovery, and follow-up.
Specialist availability and coverage can be limited.
A procedure is less reversible; color match and durability are uncertain.
Do I have to start treatment now?
No. After the diagnosis and any related health questions have been addressed, choosing no active treatment can be a deliberate option—not a failure to act. You can revisit the decision if your skin, health, or priorities change. Evidence Evidence Evidence
Why this matters
Patient and clinical guidance recognizes that treatment is optional and goals differ. You can still protect your skin and get emotional support while you wait. You can also agree on which changes to track.
What if my main goal is how my skin looks right now?
You can use camouflage, cosmetics, self-tanning products, or clothing if you want an immediate, reversible change in appearance. You can also choose not to conceal your skin. These choices do not treat the underlying pigment loss, but they can still matter to how you want to move through daily life. Evidence Evidence
Why this matters
Guidelines include camouflage among legitimate management choices and recognize the emotional and social effects of vitiligo. You can use appearance options alone, alongside clinician-directed care, only in certain situations, or not at all.
What are the prescription creams and ointments I may hear about?
Vitiligo creams include corticosteroids, Protopic (tacrolimus), Elidel (pimecrolimus), and Opzelura (ruxolitinib). These are not different brands of one cream. Each has its own approval status, evidence, risks, best body areas, follow-up needs, availability, and cost. Evidence Evidence Evidence Evidence Evidence
Why this matters
Current guidelines discuss several creams. In the United States, ruxolitinib is approved for a defined group with vitiligo. Tacrolimus, pimecrolimus, and topical corticosteroids do not have that specific US approval.
When might light treatment come up?
Narrowband UVB and targeted light are established clinician-directed options for some people with vitiligo. Treatment in a clinic and treatment at home create different practical burdens, but neither setting guarantees repigmentation or removes the need for qualified oversight. Evidence Evidence
Why this matters
Guidelines discuss narrowband UVB across vitiligo patterns and body areas, and targeted devices for more localized patches. Group results show that response can differ by body site and that not everyone repigments.
Could pills, injections, or research treatments be options for me?
They may come up in selected clinical situations, and newer immune-targeting medicines are being studied. But “promising,” “used by some specialists,” and “approved for vitiligo” mean different things. A research result or approval for another condition does not make a medicine established for your vitiligo. Evidence Evidence
Why this matters
International guidance discusses medicines that work throughout the body for selected goals, while clinical trials continue to investigate other medicines and combinations. The status, evidence, health restrictions, monitoring, and access need to be checked for the exact medicine where you live.
When might a procedure be considered?
Procedures that move or prepare pigment-producing cells are specialist options for carefully selected people with stable vitiligo. They are not an automatic next step after creams or light treatment. You also need to consider eligibility, risks, healing, access, and incomplete or uneven results. Evidence Evidence Evidence Evidence
Why this matters
Consensus and guideline sources reserve surgery for selected stable vitiligo in experienced settings. US authorization for RECELL covers color return in stable white vitiligo patches in adults under defined conditions. It does not approve every procedure or every person.
How do I decide which options are worth discussing for me?
Start with the goal you want help with. Then compare your realistic options using the same questions. Evidence Evidence Evidence
- Who was studied?
- What result is possible?
- What is still unknown?
- What are the risks and day-to-day effort?
- What follow-up and access does it need?
- What would choosing no active treatment mean?
Why this matters
Guidelines support shared decisions that account for the characteristics of vitiligo and its effect on your life. They present multiple paths rather than one treatment ladder everyone must climb.
Questions that can change the next decision
- For your clinicianGiven my diagnosis, activity, body areas, health history, and goal, which paths are realistic to compare?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianHow do the realistic paths differ in possible benefit, material harms, burden, access, and uncertainty?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianWhat would make us review, pause, or change the plan?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Narrowband UVB and targeted light are established clinician-directed options for some people with vitiligo. Treatment in a clinic and treatment at home create different practical burdens, but neither setting guarantees repigmentation or removes the need for qualified oversight.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a group-level outcome claim, but exact population extraction is still pending. It cannot publish or support an individual prediction until that review is complete.
Procedures that move or prepare pigment-producing cells are specialist options for carefully selected people with stable vitiligo. They are not an automatic next step after creams or light treatment. You also need to consider eligibility, risks, healing, access, and incomplete or uneven results.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-01-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
It establishes the US atopic-dermatitis indication, boxed warning, local effects, long-term-use precaution, and ultraviolet instructions for this product.
What it does not support
It does not approve tacrolimus for vitiligo, establish vitiligo efficacy, or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-04-30
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
Supports the US atopic-dermatitis indication, boxed warning, application-site effects, long-term-use precaution and instructions to avoid ultraviolet treatment and minimize natural or artificial sunlight.
What it does not support
It does not approve pimecrolimus for vitiligo, establish vitiligo efficacy or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- U.S. Food and Drug AdministrationRegulatory / guideline · not independentIndependence not established
- Published
- 2025-09-18
- SteadySkin last checked
- 2026-08-06
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It does not guarantee benefit, establish suitability beyond the labeled population or authorize adding phototherapy.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- U.S. Food and Drug AdministrationRegulatory / guideline · independentIndependent source
- Published
- 2023-06-16
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports FDA authorization of this device for repigmentation of stable depigmented vitiligo lesions in a defined adult population and trained professional setting.
What it does not support
It does not approve every grafting procedure, define stability for a reader or guarantee color match, durability or satisfaction.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- JAMA Dermatology (Ju HJ, et al.)Clinical research · not independentIndependence not established
- Published
- 2021-02-17
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports that multiple surgical techniques have been studied for selected stable vitiligo and that reported response and adverse effects vary by method and study.
What it does not support
Much of the evidence is nonrandomized and an author reported industry relationships; the review does not determine stability, eligibility, color match, durability or individual outcome.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · independentIndependent source
- Published
- 2022-10-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- American Academy of DermatologyPatient education · not independentIndependence not established
- Published
- 2026-04-15
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.